Facebook Twitter RSS Feed

You are here

Heart Failure

 - Running

Thanks to a Swedish study, we can add one more benefit to the list when talking about increasing down-time activity levels: reduced heart failure risks.

 - ecg, heart, electrophysiology

Beta-blockers appeared to offer no or little clinical benefit to patients with heart failure and atrial fibrillation in a study presented at the European Society of Cardiology’s annual meeting and concurrently published online Sept. 2 in The Lancet.

 - heart, cardiology, cardiac

A novel drug that combines an ARB with a neprilysin inhibitor proved superior to the ACE inhibitor enalapril, even when the latter was prescribed at its target dose, for reducing the risk of death and hospitalization for heart failure in patients with reduced ejection fraction.

 - EMERGENCY

Almost one-third of patients who visit the emergency department for acute heart failure will return two or more times within a year, results published online Aug. 19 showed. Could readmissions penalties exacerbate the problem?

 - Clock

The IN-TIME study showed an improvement in clinical outcomes in patients with heart failure who were telemonitored, according to results published online Aug. 16 in The Lancet.

 

More Stories

Thoratec buys maker of transapical systems for $35M

Thoratec, which makes implantable devices for patients with advanced heart failure, paid $35 million to acquire an Irish company that specializes in transapical surgical access systems.

Diabetes & heart failure: A delicate balancing act

Diabetes and heart failure have a very complex relationship. Having one puts a patient at risk for the other and once a patient has both, his or her condition may spiral quickly in a downward trajectory. In a viewpoint published June 18 in JAMA, physicians discussed concerns and the current state of therapies focused on caring for both diseases.

CRT benefits women with left bundle branch block more than men

Women with QRS of 130 milliseconds or greater see better outcomes than men when using cardiac resynchronization therapy (CRT). A study published online June 23 in JAMA Internal Medicine found that while women receive CRT defibrillation (CRT-D) less often than men, women with left bundle branch block and a QRS of 130 to 149 milliseconds had a 76 percent reduction in mortality and other heart failure-related events.

Transitional care for heart failure doesn’t dent 30-day readmissions

Use of home visits and multidisciplinary clinics helped to reduce all-cause readmissions and death up to six months after an index hospitalization for patients with heart failure, while telephone-based interventions also showed some success, according to a review of transitional care trials. But none seemed to lower 30-day readmission rates.

ICD use improves survival in less severe heart failure patients

Heart failure patients with left ventricular ejection fraction (LVEF) between 30 and 35 percent do better with an implantable cardioverter-defibrilators (ICD) than without, a study published June 4 in JAMA confirmed. The findings also support guideline recommendations for use of ICDs in patients with LVEF of less than 30.

Severe heart failure may put patients at risk for diabetes

Patients receiving an increased loop-diuretic dose rate of heart failure drugs may have a greater risk of developing diabetes.

CardioMEMS gets FDA approval and buyout offer

Persistence paid off for CardioMEMS, maker of a miniaturized implantable system for monitoring patients with heart failure. After several years, the company received FDA approval for its namesake device, which has opened the doors for its acquisition by St. Jude Medical.

HF patients change resuscitation preferences near end of life

Many heart failure (HF) patients change their final resuscitation decisions close to the end of life, often while in the hospital. The findings may help cardiologists better counsel these patients. 

FDA says ‘no’ to serelaxin for heart failure

The FDA followed the lead of its counterpart in Europe by rejecting a bid from Novartis to approve serelaxin as a treatment for acute heart failure. The FDA stated that it needed more proof of the drug’s efficacy.

HeartWare: Monitor VAD batteries

Heartware International has issued back-to-back warnings about its ventricular assist device (VAD), with the most recent notice involving batteries in the HeartWare Ventricular Assist System.

FDA puts Class I recall on HeartWare device

The FDA issued a Class I recall for the HeartWare Ventricular Assist Device due to a manufacturing flaw.

Heart failure stands out for costly readmissions

Congestive heart failure topped the list for 30-day readmissions of Medicare beneficiaries in 2011 and ranked among the top 10 high-volume conditions for two other payer categories in an analysis released in April.

FDA gives thumbs up to mini ICDs

The FDA approved the latest generation of Boston Scientific’s implantable cardiac devices.

FDA OKs use of biventricular pacing for less severe HF

The FDA expanded the indication for biventricular pacing using two types of cardiac resynchronization therapy devices to treat patients with atrioventricular block and mild to moderate heart failure (HF).

Circ retracts paper by its editor-in-chief

The journal Circulation retracted a 2012 article in which its editor-in-chief is a senior author, citing compromised data.

FDA approves 3 pacemaker devices

The FDA approved three St. Jude Medical pacemaker devices, including its quadripolar cardiac resynchronization therapy pacemaker.

'Bendopnea' identified as a possible symptom of heart failure

Experiencing shortness of breath while bending forward, termed “bendopnea,” could be an indicator of heart failure, according to researchers at the University of Texas Southwestern Medical Center in Dallas in a study published in the Journal of the American College of Cardiology.

Review: Diabetes drug trials should add HF hospitalization as outcome

Trials of new glucose-lowering drugs should consider hospitalization for heart failure as an outcome, according to a Personal View article published online March 13 in The Lancet. The authors argued that heart failure has not received much attention as an outcome in clinical trials of these drugs, but results have associated them with an increased risk of heart failure.

ICD-CRT may lead to fewer hospitalizations than ICD alone

Patients with heart failure who receive therapy consisting of an implantable cardioverter-defibrillator (ICD) and cardiac resynchronization therapy (CRT) have fewer hospitalizations than heart failure patients with only an ICD. The findings, published online March 7 in Circulation, were based on data from the Resynchronization-Defibrillation for Ambulatory Heart Failure Trial (RAFT).

LVAD bleeding risk varies based on patient factors

An analysis of HeartMate II left ventricular assist devices (LVADs) published in the March 11 issue of the Journal of the American College of Cardiology found that preoperative risk factors for bleeding and thrombotic events vary depending on patient demographics, including age, sex, body mass index and the cause of heart failure.